Financial Liabilities - The company has provided a financial guarantee liability of approximately SGD 4,076,000 for defaulted loans [2] - The company has approximately SGD 6,800,000 payable to the Singapore liquidating subsidiary, which has been transferred to an independent third party [3] Loan Repayment - Dr. Loh has repaid loans totaling SGD 2,519,849.68 to United Overseas Bank and DBS Bank [3] - The company aims to reach an agreement on the repayment schedule with the third party within 2025 [3] Share Issuance - There are no specific plans to issue new shares to Dr. Loh at this time [3]

2024 Annual Report 年 報 Characteristics of GEM of the Stock Exchange of Hong Kong Limited (The "Stock Exchange") 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. Given that ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 RMH HOLDINGS LIMITED （於開曼群島註冊成立之有限公司） （股份代號：8437） 截至2024年12月31日止年度的 全年業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM 的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交 所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在 風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM 上市公司普遍為中小型公司，在GEM 買賣的證券可能會較於主板買賣 的證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量 的市場。 香港交易及結算所有限公司以及聯交所對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃遵照聯交所GEM證券上市規則（「GEM上市規則」）的規定 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 RMH HOLDINGS LIMITED （於開曼群島註冊成立之有限公司） （股份代號：8437） 截至2024年6月30日止六個月的中期業績公佈 | --- | |------------------------------------------------------------------------------------| | | | 德斯控股有限公司（「 本公司 」，連同其附屬公司為「 本集團 」）董事（「 | | 事會 」）欣然宣佈本公司及其附屬公司截至 2024 年 6 月 30 日止六個月的未經審核業績。 | | 本公佈載有本公司 2024 年中期報告全文，乃符合香港聯合交易所有限公司 | | 券上市規則有關季度業績初步公佈附載資料的相關規定。 | | | | | | | | | 香港，2024年8月28日 於本公告日期，本公司執行董事為潘俊彥先生（主席）、李宗舜先生（副主席）、 陸 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 RMH HOLDINGS LIMITED （於開曼群島註冊成立之有限公司） （股份代號：8437） 2023年年報的補充公告 茲提述德斯控股有限公司（「本公司」）截至2022年12月31日止年度的年報（「2022年 年報」）及截至2023年12月31日止年度的年報（「2023年年報」，統稱「年報」）。除本 公告另有界定或文義另有規定外，本公告所用詞彙與年報所界定者具有相同涵義。 本公告旨在提供本公司與先機會計師行有限公司（「核數師」）所同意2023年年報中 有關新加坡清盤附屬公司會計賬簿及記錄範圍限制的比較數字及相關披露以及終 止合併新加坡清盤附屬公司的補充資料。 誠如2022年年報中有關本集團截至2022年12月31日止年度的綜合財務報表（「2022 年綜合財務報表」）的核數師報告所披露，由於董事認為本集團於2022年11月（「終 止合併日期」）已失去對新加坡清盤附屬公司的控制權，故本集團已終止合併新 ...

Financial Performance - The unaudited revenue of RMH Holdings Limited for the nine months ended 30 September 2023 was approximately S$2,250,000, representing a decrease of approximately S$169,000 or 7.0% compared to S$2,419,000 for the same period in 2022[8]. - The unaudited loss for the Group was approximately S$3,921,000 for the nine months ended 30 September 2023, a decrease of approximately S$1,579,000 or 28.7% from a loss of S$5,500,000 for the same period in 2022[8]. - Loss per share for the Company was approximately 0.31 Singapore cents for the nine months ended 30 September 2023, compared to 0.47 Singapore cents for the same period in 2022[8]. - The company reported a loss before taxation of S$3,921,000 for the nine months ended September 30, 2023, compared to a loss of S$5,500,000 in the same period of 2022, indicating an improvement of about 29%[94]. - The total comprehensive loss for the year to date was S$3,790,000, which includes an other comprehensive loss of S$131,000, highlighting ongoing challenges in financial performance[11]. - The company’s total comprehensive loss for the nine months ended September 30, 2023, reflects ongoing operational challenges and market conditions affecting profitability[11]. Revenue Breakdown - Dental services generated revenue of S$1,472,000 for the nine months ended September 30, 2023, with trading sales contributing S$778,000[86]. - Revenue from healthcare services was recognized entirely at a point in time, with no revenue recognized over time during the reporting period[86]. - Revenue from prescription and dispensing services is recognized when the patient obtains control of the medication and skincare products[78]. - Revenue from trading sales is recognized when control of the goods is transferred to the customer upon delivery[81]. - Revenue from aesthetic services, consultation services, treatment services, and trading sales, with performance obligations generally satisfied within one day[71][79][81]. Operating Expenses - Employee benefits expense decreased to S$2,011,000 for the nine months ended 30 September 2023 from S$2,396,000 in the same period in 2022[9]. - Other operating expenses decreased by approximately S$271,000 or 9.3%, from approximately S$2,910,000 for the nine months ended September 30, 2022 to approximately S$2,639,000 for the nine months ended September 30, 2023[144]. - The Group's cost of consumables and medical supplies used was approximately S$1,000,000 for the nine months ended September 30, 2023, down from approximately S$1,099,000 in 2022[123][127]. - Interest expenses on borrowings decreased to S$4,000 for the nine months ended September 30, 2023, down from S$14,000 in 2022, reflecting a reduction of approximately 71%[92]. Corporate Governance - The company complied with all applicable code provisions of the Corporate Governance Code during the nine months ended September 30, 2023[169]. - The board is committed to high standards of corporate governance to manage business risks and enhance transparency[168]. - The company will continue to review and improve its corporate governance practices[168]. - All directors confirmed compliance with the code of conduct regarding securities transactions throughout the nine months ended September 30, 2023[181]. Shareholder Information - The company did not recommend any dividend for the nine months ended September 30, 2023, consistent with the same period in 2022[102]. - The company has adopted a share option scheme, granting a total of 60,000,000 share options to ten directors and eligible participants at an exercise price of HK$0.109 per share[174]. - The total number of share options as of September 30, 2023, is 30,000,000, with 18,000,000 exercised and 12,000,000 lapsed[177]. - As of September 30, 2023, Brisk Success holds 210,024,000 shares, representing approximately 15.77% of the company's shareholding[165]. Strategic Focus - The core business operations are shifting towards dental implant services, with a two-year business development plan established in 2022[111][115]. - The Company sees significant market potential for dental implant services in mainland China, driven by a large population and aging demographics[112][115]. - The Group will focus resources on the continuous development of dental services and maintain a prudent investment strategy[113][115]. - The nature of the Group's main business has shifted from dermatology aesthetic services to dental care and dental implant services due to previous operational changes[118][119]. Compliance and Audit - The Audit Committee reviewed the unaudited condensed consolidated financial statements for the nine months ended September 30, 2023[194]. - The company established the Audit Committee on September 22, 2017, in compliance with GEM Listing Rules[193].

Revenue and Business Performance - The Group's revenue from dental services reached approximately S$2,039,000, an increase of approximately S$1,124,000 or 122.8% compared to S$915,000 for the year ended December 31, 2022, accounting for approximately 64.1% of total revenue[18] - The Dental Business achieved sales of S$2,039,000 for the year ended December 31, 2023, representing an increase of 122.8% compared to S$915,000 in 2022[40] - The increase in dental service revenue reflects a significant shift in the Group's operational focus and market strategy[18] - For the year ended December 31, 2023, the revenue from health products, nutritional supplements, and related medical beauty products was approximately S$1,141,000, a decrease of about S$2,185,000 or 65.7% compared to S$3,326,000 for the year ended December 31, 2022[44] - As of December 31, 2023, the trading amount of healthcare products and related aesthetics products was approximately S$1,141,000, a decrease of 65.7% from S$3,326,000 in 2022[39] Business Strategy and Transformation - The core business operations will shift to dental implant services, with a two-year business development plan established in 2022[18] - The Group's main business has transitioned from dermatology aesthetic services to dental care and dental implant services due to liquidation and judicial management of its Singapore subsidiaries in 2022[17] - The Group's strategic focus will be on expanding its dental services while also reviving its dermatology aesthetic services[19] - The company will focus on developing its core business operations in mainland China and Hong Kong, particularly in dental and dermatology services[24][33] - The vast population base and aging phenomenon in mainland China provide significant market potential for the company's development plans[24][33] - The overall business transformation is aimed at enhancing the Group's market position and operational efficiency[19] Financial Performance and Costs - Other operating income increased to approximately S$361,000 in 2023, up from S$318,000 in 2022, mainly due to gains from rental income[41] - Consumables and medical supplies used decreased to approximately S$1,133,000 in 2023, down 68% from S$3,534,000 in 2022, representing 36% of total revenue[42][43] - Employee benefits expense decreased to approximately S$2,363,000 for the year ended December 31, 2023, down from S$3,221,000 for the year ended December 31, 2022, primarily due to a reduction in staff headcount[49] - Other operating expenses decreased by approximately S$301,000 or 14% from approximately S$2,170,000 for the year ended December 31, 2022, to approximately S$1,869,000 for the year ended December 31, 2023[56] - Finance costs for the year ended December 31, 2023, were approximately S$55,000, a decrease of about S$163,000 compared to S$218,000 for the year ended December 31, 2022[57] - The loss for the year from continuing operations was approximately S$6,853,000 for the year ended December 31, 2023, a decrease from a loss of approximately S$13,127,000 for the year ended December 31, 2022[58] Governance and Compliance - The Company aims to improve corporate governance, including enhancing internal control systems and compliance training[19] - The Company emphasizes the importance of compliance checks and supervision measures in its governance framework[19] - The Group has complied with relevant laws and regulations with no material breaches reported for the year ended December 31, 2023[105] - There were no significant disputes with key stakeholders during the year ended December 31, 2023, indicating strong relationships[106] Shareholder and Director Information - The Board does not recommend the payment of a final dividend for the year ended December 31, 2023[65] - As of December 31, 2023, the Group reported no distributable reserves available for distribution to shareholders under the Companies Law of the Cayman Islands[110] - The Directors' fees are subject to Shareholders' approval at general meetings, with other emoluments determined by the Board[134] - The Group has established a Remuneration Committee to review and recommend remuneration policies[135] - The independent non-executive Directors confirmed compliance with the non-competition undertakings for the year ended December 31, 2023[191] Employee and Operational Changes - The Group had a total of 32 employees as of December 31, 2023, down from 50 in 2022[81] - The total employee costs for the year ended December 31, 2023, were approximately S$2,363,000, a decrease from approximately S$3,221,000 in 2022[81] - The company has not operated any retirement benefit schemes for its employees, except for payments to the Central Provident Fund in Singapore and a Mandatory Provident Fund Scheme in Hong Kong[143] Share Option Scheme - The Company adopted a Share Option Scheme on September 22, 2017, to incentivize and reward eligible persons for their contributions[161] - The total number of shares available for issue under the Share Option Scheme must not exceed 10% of all shares in issue as of the Listing Date unless fresh approval is obtained from shareholders[167] - As of the report date, the outstanding number of share options available for grant under the Share Option Scheme is nil[168] - A total of 60,000,000 share options were granted on September 29, 2022, at an exercise price of HK$0.109 per share[181] - The options granted are exercisable from September 29, 2022, to September 28, 2032[181]

Financial Performance - The unaudited revenue for the Group for the three months ended March 31, 2023, was approximately S$309,000, a decrease of approximately S$450,000 or 59.29% compared to S$759,000 for the same period in 2022[7]. - The unaudited loss for the Group was approximately S$1,827,000 for the three months ended March 31, 2023, representing a decrease in losses of approximately S$250,000 or 12.04% compared to S$2,077,000 for the same period in 2022[7]. - Loss per share for the Company was approximately 0.15 Singapore cents for the three months ended March 31, 2023, compared to 0.22 Singapore cents for the same period in 2022[7]. - Total comprehensive loss for the period was S$1,535,000 for the three months ended March 31, 2023, compared to S$2,055,000 for the same period in 2022[8]. - The company reported a loss for the period of S$1,713,000 for the first quarter of 2023, compared to a loss of S$2,529,000 for the same period in 2022, representing a reduction in losses of approximately 32%[10]. - The Group reported a foreign currency translation loss of S$292,000 for the three months ended March 31, 2023, compared to a gain of S$22,000 for the same period in 2022[8]. - The company recorded a loss of approximately S$1,827,000 for the three months ended March 31, 2023, a decrease of approximately S$250,000 or 12.04% compared to a loss of approximately S$2,077,000 for the same period in 2022[88]. Revenue Breakdown - Revenue from dental services amounted to S$264,000, while trading sales contributed S$45,000, indicating a significant shift in revenue sources[31]. - Revenue from external customers in Hong Kong was S$45,000, down from S$759,000 in the previous year, while revenue from China was S$264,000, which was not reported in the prior year[33]. - Revenue from Dental Services amounted to S$264,000, accounting for approximately 85% of total revenue for the three months ended March 31, 2023[60][61]. - Trading Sales contributed approximately S$45,000, representing a significant decrease of approximately S$714,000 compared to S$759,000 for the three months ended March 31, 2022[63][68]. - Total revenue for the three months ended March 31, 2023, was S$309,000, a decrease of 59.3% compared to S$759,000 for the same period in 2022[28]. Operating Income and Expenses - Other operating income increased to S$572,000 for the three months ended March 31, 2023, compared to S$73,000 for the same period in 2022[8]. - Other operating income for the three months ended March 31, 2023, was approximately S$572,000, which represented an increase of S$499,000 compared to S$73,000 for the same period in 2022[64][69]. - Employee benefits expense was S$797,000 for the three months ended March 31, 2023, compared to S$765,000 for the same period in 2022[8]. - Other operating expenses rose by approximately S$296,000 or 30.42%, from approximately S$973,000 for the three months ended March 31, 2022, to approximately S$1,269,000 for the same period in 2023[85]. - Consumables and medical supplies used amounted to approximately S$163,000 for the three months ended March 31, 2023, down from S$638,000 in the same period in 2022[65][70]. Corporate Governance and Compliance - The Company has adopted a code of conduct for securities transactions by directors, which was complied with throughout the three months ended March 31, 2023[119]. - The Audit Committee consists of three independent non-executive Directors, ensuring oversight of financial reporting and internal controls[133]. - The company complied with all applicable code provisions of the Corporate Governance Code during the three months ended March 31, 2023[107]. - The independent non-executive Directors confirmed compliance with the non-competition undertakings for the three months ended March 31, 2023[125]. - The Board is committed to high standards of corporate governance to manage business risks and enhance transparency[106]. Future Outlook and Strategic Focus - The Company will shift its core business operations to dental implant services, supported by a two-year business development plan established in 2022[51][55]. - The Company identifies a significant market potential for dental implant services in mainland China, driven by a large population and aging demographics[52][55]. - The Group aims to concentrate resources on the continuous development of dental services while maintaining a prudent investment strategy[53][55]. - Future outlook remains cautious due to ongoing market challenges and the need for strategic adjustments in operations[29]. Shareholder Information - As of March 31, 2023, Dr. Loh Teck Hiong holds 210,024,000 shares, representing approximately 15.77% of the company's total shareholding[97]. - Mr. Lee Chung Shun was allotted 6,000,000 shares on January 12, 2023, following the full exercise of share options granted under the Share Option Scheme[97]. - Brisk Success, a beneficial owner, holds 210,024,000 shares, equivalent to 15.77% of the total shareholding[104]. - HK MZ Health Investment Management Group Limited holds 132,968,000 shares, accounting for 9.98% of the total shareholding[104]. - The total number of share options granted as of March 31, 2023, is 30,000,000, with 18,000,000 exercised and 12,000,000 lapsed[115].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 RMH HOLDINGS LIMITED （於開曼群島註冊成立之有限公司） （股份代號：8437） 截至2023年12月31日止年度的 全年業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM 的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交 所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在 風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM 上市公司普遍為中小型公司，在GEM 買賣的證券可能會較於主板買賣 的證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量 的市場。 香港交易及結算所有限公司以及聯交所對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃遵照聯交所GEM證券上市規則（「GEM上市規則」）的規定 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 RMH HOLDINGS LIMITED （於開曼群島註冊成立之有限公司） （股份代號：8437） 截至2023年9月30日止九個月的第三季度業績公佈 德斯控股有限公司（「本公司」，連同其附屬公司為「本集團」）董事（「董事」）會（「董 事會」）欣然宣佈本公司及其附屬公司截至2023年9月30日止九個月的未經審核業 績。本公佈載有本公司2023年第三季度報告全文，乃符合香港聯合交易所有限公司 GEM證券上市規則有關季度業績初步公佈附載資料的相關規定。 承董事會命 德斯控股有限公司 主席及執行董事 潘俊彥 香港，2024年3月22日 於本公告日期，執行董事為潘俊彥先生（主席）、陸偉明先生、李宗舜先生及崔晗 先生，以及獨立非執行董事為周穎楠先生、楊博文先生及張佇綸先生。 本公告乃遵照香港聯合交易所有限公司GEM 證券上市規則而提供有關本公司之 資料。董事就此共同及個別承擔全部責任。董事經作出一切合理查詢後確認 ...